Scholar Rock Holding (SRRK) EBITDA Margin (2019 - 2022)
Scholar Rock Holding's (SRRK) quarterly EBITDA Margin came in at 20.89% in Q1 2022, up 55700.0% year-on-year from N/an in Q1 2021, and up 97.61% quarter-over-quarter from 873.4% in Q4 2021.
Scholar Rock Holding (SRRK) EBITDA Margin (2019 - 2022) Analysis & Trends
Scholar Rock Holding's EBITDA Margin history runs 4 years deep, the most recent figure standing at 20.89% for Q1 2022.
- On a quarterly basis, EBITDA Margin rose 55700.0% year-over-year to 20.89% in Q1 2022; TTM through Dec 2022 was 404.81%, a 28567.0% increase from a year earlier, with the FY2022 full-year figure at 404.81%, up 28567.0% from the prior year.
- EBITDA Margin grew to 20.89% in Q1 2022 per SRRK's latest filing, from 873.4% in the prior quarter.
- Across five years, EBITDA Margin topped out at 20.89% in Q1 2022 and bottomed at 873.4% in Q4 2021.
- The 4-year median for EBITDA Margin is 499.03% (2020), against an average of 489.35%.
- Across the five-year window, EBITDA Margin sank 59668 bps in 2020 and soared 55700 bps in 2022, its largest moves.
- Year by year, EBITDA Margin stood at 163.04% in 2019, then slumped by 366 bps to 759.72% in 2020, then dropped by 15 bps to 873.4% in 2021, then surged by 98 bps to 20.89% in 2022.
- Per Business Quant, the three latest SRRK EBITDA Margin figures stand at 20.89% (Q1 2022), 873.4% (Q4 2021), and 678.57% (Q3 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -20.89% |
| Dec 31, 2021 | -873.40% |
| Sep 30, 2021 | -678.57% |
| Jun 30, 2021 | -658.82% |
| Mar 31, 2021 | -577.89% |
| Dec 31, 2020 | -759.72% |
| Sep 30, 2020 | -777.68% |
| Jun 30, 2020 | -499.03% |
| Mar 31, 2020 | -351.77% |
| Dec 31, 2019 | -163.04% |
| Sep 30, 2019 | -358.32% |
| Jun 30, 2019 | -265.65% |
| Mar 31, 2019 | -376.79% |